Amphix Bio is pioneering a transformative therapeutic platform for regenerative medicine that leverages supramolecular chemistry. This innovative approach encodes interactions between molecules to activate regenerative signals, enhancing communication with cell receptors. The technology utilizes peptide amphiphile molecules to create dynamic 3D scaffolds that mimic the natural extracellular environment, facilitating tissue regeneration. With over 20 years of foundational research led by Professor Samuel Stupp at Northwestern University, Amphix Bio's platform has been validated through extensive peer-reviewed publications and patents, demonstrating its potential across various therapeutic areas.

The company's pipeline includes several promising applications aimed at addressing significant medical needs. Their bone regeneration program offers an off-the-shelf graft substitute for spinal fusion surgeries, while the neural regeneration program focuses on an injectable therapy designed to restore function after acute spinal cord injuries. Additionally, Amphix Bio is developing a cartilage regeneration therapy for knee injuries, which can be administered during minimally invasive procedures. These therapies are designed to overcome the limitations of current treatment options, such as safety concerns associated with cell therapies, by providing effective, cell-free solutions that are easy to manufacture and shelf-stable.

United States

Amphix Bio spun out from Northwestern University in Chicago, IL in 2021. The company is developing a new class of supramolecular therapies that instruct cells to initiate regenerative processes and restore function lost from injury, disease, or aging. These therapies contain tens of thousands of biological signals that trigger targeted signaling pathways while forming scaffolds to support tissue growth. Amphix Bio's goal is to use regenerative medicine to increase human healthspans — the length of time that people can live productive, fulfilling lives.

Amphix Bio

Company Details